Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Fireworks

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Mar 03, 2021 5:46pm

206 Views

Post# 32710977

RE:RE:RE:RE:Fireworks

JimmyJ wrote:
Yeah, that was all for today. It was a formal press release though. Wondering if Crow's message last night about a NR and fireworks was a coincidence? Maybe more to come?

https://antibethera.com/news/antibe-therapeutics-to-present-at-upcoming-virtual-investor-conferences/

Crow's comment is likely related more to the expected IND filing for OTENA.
Dan said it was weeks away on January 11th - so - if we look at the time he said weeks away for the shareholder update, March/April is likely our timeframe.
Hoping it's more likely in March - as this is a busy month for marketing the company.
An IND filing would come in handy at this time (IMO).

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December